



# P-REX1-Independent, Calcium-Dependent RAC1 Hyperactivation in Prostate Cancer

Martin J. Baker, Martín C. Abba, Rafael Garcia-Mata and Marcelo G. Kazanietz




**Figure S1.** Rac1-GTP and Cdc42-GTP levels in the androgen dependent VCaP cells and the effect of PI3K and G $\beta\gamma$  inhibition and Vav2/3 silencing in DU145 and PC3 cells (A) Representative Western blots of PBD pull-down assays showing Rac1-GTP and Cdc42-GTP in VCaP and PC3 cells growing in the presence of 10% FBS. (B) Similar experiments were carried out after 24 h serum starvation. (C–D) Densitometric analysis of Rac1-GTP/total Rac1 and Cdc42-GTP/total Cdc42. Results normalized to VCaP cells are expressed as the mean  $\pm$  S.E. ( $n = 3$ ). (E) Effect of the PI3K inhibitor BKM120 (2  $\mu$ M, 60 min) on basal Cdc42-GTP levels in DU145 and PC3 prostate cells, and on HRG-stimulated (20 ng/mL,


5 min) MCF-7 breast cancer cells. (F) Effect of the G $\beta\gamma$  inhibitor gallein (10  $\mu$ M, 30 min) on basal Cdc42-GTP levels in DU145 and PC3 prostate cells, and on HRG-stimulated (20 ng/mL, 5 min) MCF-7 breast cancer cells. For E and F, *lower panels* are representative experiments, and *upper panels*, densitometric analysis of Cdc42-GTP levels normalized to total Cdc42. Results are expressed as the mean  $\pm$  S.E. ( $n = 4-6$ ) relative to non-treated cells (PC3 and DU145) or HRG-stimulated cells (MCF-7). (G) PC3 cells were transfected with Vav2, Vav3 or non-target control (NTC) RNAi duplexes, and the Rac1-GTP levels determined using a PBD pull-down assay after 48 h. *Left panel*, representative mRNA fold-change after RNAi. *Middle panel*, representative Rac1-GTP pulldown experiment. *Right panel*, densitometric analysis of Rac1-GTP levels normalized to total Rac1. Results, relative to NTC, are expressed as the mean  $\pm$  S.E. ( $n = 3$ ).




**Figure S2.** Association of  $\beta$ 2-chimaerin expressed in PC3 and MCF-7 cells with a constitutively active Rac1<sup>Q61L</sup> mutant and insensitivity of Rac1-GTP in PC3 cells to Rho activation. (A) PC3 and MCF7 cells were infected with  $\beta$ 2-chimaerin AdV (100 pfu/cell). After 16 h, cells were lysed and recombinant GST-fused Rac1<sup>Q61L</sup> bait was used to pull-down  $\beta$ 2-chimaerin. A representative experiment is shown. (B) PC3 cells were treated for the indicated times with 1  $\mu$ g/mL Rho Activator II and Rac1-GTP levels determined using the PBD pulldown assay. *Left panel*, representative experiment. *Right panel*, densitometric analysis of Rac1-GTP levels normalized to total Rac1 levels. Results are expressed as the mean  $\pm$  S.E. ( $n = 3$ ) relative to non-treated cells.



**Figure S3.** Expression of Rac-GEFs in PC3 cells. **(A)** Expression of Rac-GEFs in the stable non-target control (shNTC1) PC3 cell line by qPCR. Results are expressed as  $\Delta CT$ , using  $\beta 2$ -microglobulin as a housekeeping gene. **(B)** mRNA expression levels of the indicated Rac-GEF in each of the stable depleted cell lines are displayed as fold-change relative to the shNTC1 cell line. The depletion of FGD5 resulted in undetectable levels of mRNA in the corresponding stably depleted cell line.



**Figure S4.** Silencing ALS2, TIAM2 or DOCK4 does not affect Cdc42-GTP levels. **(A)** Representative mRNA expression fold-change for ALS2, TIAM2 and DOCK4 48 h after transfection of RNAi duplexes. **(B)** PC3 cells were transfected with RNAi targeting ALS2, TIAM2, DOCK4 or a non-target control (NTC), and the Rac1-GTP determined using a PBD assay after 48 h. *Top panel*, representative experiment. *Bottom panel*, densitometric analysis of Cdc42-GTP/total Cdc42. Results, relative to parental cells, are expressed as the mean  $\pm$  S.E. ( $n = 3$ ).



**Figure S5.** SmgGDS, Grb2 and IQGAP1 silencing have no effect on Rac1-GTP levels. **(A)** PC3 and DU145 cells were transfected with SmgGDS targeting or non-target control (NTC) RNAi duplexes for 48 h, including a 24 h serum starvation prior to the determination of Rac1-GTP levels using a PBD pull-down assay. *Left panel*, representative mRNA fold-change after RNAi. *Middle panel*, representative Rac1-GTP pulldown experiment. *Right panel*, densitometric analysis of Rac1-GTP levels normalized to total Rac1. Results, relative to NTC, are expressed as the mean  $\pm$  S.E. ( $n = 3$ ). **(B)** PC3 cells were transfected with Grb2 targeting or non-target control (NTC) RNAi duplexes for 48 hours, including a 24 h serum starvation prior to the determination of Rac1-GTP levels using a PBD pull-down assay. *Left panel*, representative mRNA fold-change after RNAi. *Right panel*, representative Rac1-GTP pulldown experiment. **(C)** PC3 cells were transfected with IQGAP1 or NTC RNAi duplexes for 48 h, including a 24 h serum starvation prior to the determination of Rac1-GTP levels. *Left panel*, representative Rac1-GTP pulldown experiment. *Right panel*, densitometric analysis of Rac1-GTP levels normalized to total Rac1. Results, relative to NTC, are expressed as the mean  $\pm$  S.E. ( $n = 4$ ).

**Table S1.** Proteomics of Rac1G15A binding proteins. See Excel file.

